A Chemical Modulator of p53 Transactivation that Acts as a Radioprotective Agonist

Inhibiting p53-dependent apoptosis by inhibitors of p53 is an effective strategy for preventing radiation-induced damage in hematopoietic lineages, while p53 and p21 also play radioprotective roles in the gastrointestinal epithelium. We previously identified some zinc(II) chelators, including 8-quinolinol derivatives, that suppress apoptosis in attempts to discover compounds that target the zinc-binding site in p53. We found that 5-chloro-8-quinolinol (5CHQ) has a unique p53-modulating activity that shifts its transactivation from proapoptotic to protective responses, including enhancing p21 induction and suppressing PUMA induction. This p53-modulating activity also influenced p53 and p53-target gene expression in unirradiated cells without inducing DNA damage. The specificity of 5CHQ for p53 and p21 was demonstrated by silencing the expression of each protein. These effects seem to be attributable to the sequence-specific alteration of p53 DNA-binding, as evaluated by chromatin immunoprecipitation and electrophoretic mobility shift assays. In addition, 5-chloro-8-methoxyquinoline itself had no antiapoptotic activity, indicating that the hydroxyl group at the 8-position is required for its antiapoptotic activity. We applied this remarkable agonistic activity to protecting the hematopoietic and gastrointestinal system in mouse irradiation models. The dose reduction factors of 5CHQ in total-body and abdominally irradiated mice were about 1.2 and 1.3, respectively. 5CHQ effectively protected mouse epithelial stem cells from a lethal dose of abdominal irradiation. Furthermore, the specificity of 5CHQ for p53 in reducing the lethality induced by abdominal irradiation was revealed in Trp53-KO mice. These results indicate that the pharmacologic upregulation of radioprotective p53 target genes is an effective strategy for addressing the gastrointestinal syndrome. Mol Cancer Ther; 17(2); 432–42. ©2017 AACR. See all articles in this MCT Focus section, “Developmental Therapeutics in Radiation Oncology.”

[1]  D. V. van Bekkum,et al.  Protection from haemopoietic death by shielding versus grafting of bone-marrow. , 1974, International journal of radiation biology and related studies in physics, chemistry, and medicine.

[2]  J. Hendry,et al.  Radiobiology for the Radiologist , 1979, British Journal of Cancer.

[3]  T. Seno,et al.  Selection of mammalian thymidine auxotrophic cell mutants defective in thymidylate synthase by their reduced sensitivity to methotrexate , 1981, Somatic cell genetics.

[4]  Susan Budavari,et al.  The Merck index : an encyclopedia of chemicals, drugs, and biologicals , 1983 .

[5]  E. Travis,et al.  The influence of bone marrow depletion on intestinal radiation damage. , 1989, International journal of radiation oncology, biology, physics.

[6]  H. Withers,et al.  Comparison of the gastrointestinal syndrome after total-body or total-abdominal irradiation. , 1989, Radiation research.

[7]  S. Roberts,et al.  The temporal and spatial changes in cell proliferation within the irradiated crypts of the murine small intestine. , 1990, International journal of radiation biology.

[8]  M. Haas,et al.  Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines , 1990, Molecular and cellular biology.

[9]  M. Goitein,et al.  Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.

[10]  J. Shay,et al.  A transcriptionally active DNA-binding site for human p53 protein complexes , 1992, Molecular and cellular biology.

[11]  T. Yagi,et al.  Enhanced proliferative potential in culture of cells from p53-deficient mice. , 1993, Oncogene.

[12]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[13]  J N Weinstein,et al.  Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. , 1997, Cancer research.

[14]  R. Kanamaru,et al.  Screening the p53 status of human cell lines using a yeast functional assay , 1997, Molecular carcinogenesis.

[15]  B. Endlich,et al.  Ionizing radiation-induced, Bax-mediated cell death is dependent on activation of cysteine and serine proteases. , 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[16]  H. Ishikawa,et al.  Apoptosis and appearance of Trp53-positive micronuclei in murine tumors with different radioresponses in vivo. , 1999, Radiation research.

[17]  K. Matthews,et al.  Protein-DNA binding correlates with structural thermostability for the full-length human p53 protein. , 2001, Biochemistry.

[18]  K. Shinohara,et al.  Evaluation of the relative contribution of p53-mediated pathway in X-ray-induced apoptosis in human leukemic MOLT-4 cells by transfection with a mutant p53 gene at different expression levels , 2001, Cell and Tissue Research.

[19]  X. Roucou,et al.  Conformational change of Bax: a question of life or death , 2001, Cell Death and Differentiation.

[20]  Zvi Fuks,et al.  Endothelial Apoptosis as the Primary Lesion Initiating Intestinal Radiation Damage in Mice , 2001, Science.

[21]  M. Sporn,et al.  Chemoprevention: an essential approach to controlling cancer , 2002, Nature Reviews Cancer.

[22]  B. Katzenellenbogen,et al.  Defining the "S" in SERMs , 2002, Science.

[23]  M. Kastan,et al.  DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation , 2003, Nature.

[24]  Stewart N Loh,et al.  Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain. , 2003, Biochemistry.

[25]  J. Goldblum,et al.  Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice , 2004, Oncogene.

[26]  G. Evan,et al.  The pathological response to DNA damage does not contribute to p53-mediated tumour suppression , 2006, Nature.

[27]  K. Ohtomo,et al.  Sodium orthovanadate suppresses DNA damage-induced caspase activation and apoptosis by inactivating p53 , 2006, Cell Death and Differentiation.

[28]  F. Kittrell,et al.  Ataxia telangiectasia-mutated and p53 are potential mediators of chloroquine-induced resistance to mammary carcinogenesis. , 2007, Cancer research.

[29]  J. Butler,et al.  Zn(2+)-dependent misfolding of the p53 DNA binding domain. , 2007, Biochemistry.

[30]  A. Fersht,et al.  Structure–function–rescue: the diverse nature of common p53 cancer mutants , 2007, Oncogene.

[31]  Joseph A. DiDonato,et al.  An Agonist of Toll-Like Receptor 5 Has Radioprotective Activity in Mouse and Primate Models , 2008, Science.

[32]  A. Gudkov,et al.  Radioprotection: smart games with death. , 2010, The Journal of clinical investigation.

[33]  E. Yorke,et al.  Use of normal tissue complication probability models in the clinic. , 2010, International journal of radiation oncology, biology, physics.

[34]  S. Korsmeyer,et al.  p53 Controls Radiation-Induced Gastrointestinal Syndrome in Mice Independent of Apoptosis , 2009, Science.

[35]  Shin Aoki,et al.  Sodium orthovanadate inhibits p53-mediated apoptosis. , 2010, Cancer research.

[36]  A. Enomoto,et al.  Cycloheximide suppresses radiation-induced apoptosis in MOLT-4 cells with Arg72 variant of p53 through translational inhibition of p53 accumulation. , 2011, Journal of radiation research.

[37]  Yi Tang,et al.  Phosphorylation of Tip60 by GSK-3 determines the induction of PUMA and apoptosis by p53. , 2011, Molecular cell.

[38]  Mohammad Hedayati,et al.  Chloroquine improves survival and hematopoietic recovery after lethal low-dose-rate radiation. , 2012, International journal of radiation oncology, biology, physics.

[39]  Dong Yu,et al.  TLR9 Agonist Protects Mice from Radiation-Induced Gastrointestinal Syndrome , 2012, PloS one.

[40]  A. Levine,et al.  Allele-specific p53 mutant reactivation. , 2012, Cancer cell.

[41]  Potent inhibition of dinuclear zinc(II) peptidase, an aminopeptidase from Aeromonas proteolytica, by 8-quinolinol derivatives: inhibitor design based on Zn2+ fluorophores, kinetic, and X-ray crystallographic study , 2012, JBIC Journal of Biological Inorganic Chemistry.

[42]  D. Kirsch,et al.  p21 Protects “Super p53” Mice from the Radiation-Induced Gastrointestinal Syndrome , 2012, Radiation research.

[43]  R. Weichselbaum,et al.  New Paradigms and Future Challenges in Radiation Oncology: An Update of Biological Targets and Technology , 2013, Science Translational Medicine.

[44]  B. Wang,et al.  Sodium orthovanadate (vanadate), a potent mitigator of radiation-induced damage to the hematopoietic system in mice , 2013, Journal of radiation research.

[45]  B. Wang,et al.  Evaluation of Zinc (II) chelators for inhibiting p53-mediated apoptosis , 2013, Oncotarget.

[46]  Bing Wang,et al.  AS-2, a novel inhibitor of p53-dependent apoptosis, prevents apoptotic mitochondrial dysfunction in a transcription-independent manner and protects mice from a lethal dose of ionizing radiation. , 2014, Biochemical and biophysical research communications.

[47]  F. D. de Sauvage,et al.  Lgr5+ stem cells are indispensable for radiation-induced intestinal regeneration. , 2014, Cell stem cell.

[48]  Bing Wang,et al.  Design and synthesis of 8-hydroxyquinoline-based radioprotective agents. , 2014, Bioorganic & medicinal chemistry.

[49]  Small molecule compounds targeting the p53 pathway: are we finally making progress? , 2014, Apoptosis.

[50]  Hayato Ohwada,et al.  Comparison of Random Forest and SVM for Raw Data in Drug Discovery: Prediction of Radiation Protection and Toxicity Case Study , 2016 .